Lipidomics in the study of lipid metabolism: Current perspectives in the omic sciences

Gene

Volumn 554, Issue 2, 2015, Pages 131-139

  Rolim, Ana Emília Holanda ^a   Henrique Araújo, Ricardo ^a   Ferraz, Eduardo Gomes ^a   de Araújo Alves Dultra, Fátima Karoline ^a   Fernandez, Luzimar Gonzaga ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Lipids; Metabolomics; Pharmacolipidomics

Indexed keywords

LIPID; BIOLOGICAL MARKER;

LIPID ANALYSIS; LIPID METABOLISM; LIPIDOMICS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; REVIEW; CHEMISTRY; COMPUTER PROGRAM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; HUMAN; METABOLISM; PROCEDURES; SYSTEMS BIOLOGY;

BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; HUMANS; LIPID METABOLISM DISORDERS; LIPIDS; MASS SPECTROMETRY; METABOLOMICS; SOFTWARE; SYSTEMS BIOLOGY;

EID: 84910118090     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.10.039     Document Type: Review

References (96)

1. Barrera N.P., Zhou M., Robinsonet C.V. The role of lipids in defining membrane protein interactions: insights from mass spectrometry. Trends Cell Biol. 2013, 23:1-8.
2. Beger R.D., Schnackenberg L.K., Holland R.D., Li D., Dragan Y. Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma. Metabolomics 2006, 2:125-134.
3. Beh C.C., Mammucari R., Foster N.R. Lipids-based drug carrier systems by dense gas technology: a review. Chem. Eng. J. 2012, 188:1-14.
4. Bergheanu S.C., Reijmers T., Zwinderman A.H., Bobeldijk I., Ramaker R., Liem A.H., van der Greef J., Hankemeier T., Jukema J.W. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr. Med. Res. Opin. 2008, 24:2477-2487.
5. Blaho V.A., Buczynski M.W., Brown C.R., Dennis E.A. Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of lyme arthritis. J. Biol. Chem. 2009, 284:21599-21612.
6. Brown M.S., Kovanem P.T., Goldstein J.L. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981, 212:628-635.
7. Brügger B. Lipidomics: analysis of the lipid composition of cells and subcellular organelles by electrospray ionization mass spectrometry. Annu. Rev. Biochem. 2014, 83:79-98.
8. Byrnes R.W., Fahy E., Subramaniam S.A. Laboratory Information Management System for high-throughput experimental lipidomics: Minimal Information Required for the Analysis of Lipidomics Experiments (MIALE). JALA 2007, 12:230-238.
9. Dwivedi P., Schultz A.J., Hill H.H. Metabolic profiling of human blood by high-resolution ion mobility mass spectrometry (IM-MS). Int. J. Mass Spectrom. 2010, 298:78-90.
10. Eisenberg S., Levy R.L. Lipoprotein metabolism. J. Lipid Res. 1995, 13:1-89.
11. Fahy E., Subramaniam S., Brown H.A., Glass C.K., Merrill A.H., Murphy R.C., Raetz C.R., Russell D.W., Seyama Y., Shaw W., Shimizu T., Spener F., van Meer G., VanNieuwenhze M.S., White S.H., Witztum J.L., Dennis E.A. A comprehensive classification system for lipids. J. Lipid Res. 2005, 46:839-862.
12. Fahy E., Subramanium S., Murphy R.C., Nishijima N., Raetz C.R.H., Shimizu T., Spener F., van Meer G., Wakelam M.J.O., Dennis E.A. Update of the LIPID MAPS comprehensive classification system for lipids. J. Lipid Res. 2009, 9:14.
13. Fiehn O. Extending the breadth of metabolite profiling by gas chromatography coupled to mass spectrometry. Trends Anal. Chem. 2008, 27:261-269.
14. Fuchs B., Schiller J., Wagner U., Häntzschel H., Arnold K. The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin. Biochem. 2005, 38:925-933.
15. Fujiwaki T., Yamaguchi S., Tasaka M., Sakura N., Taketomi T. Application of delayed extraction-matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in pericardial fluid, peritoneal fluid and serum from Gaucher disease patients. J. Chromatogr. B 2002, 776:115-123.
16. Fuller M., Sharp P.C., Rozaklis T., Whitfield P.D., Blacklock D., Hopwood J.J., Meikle P.J. Urinary lipid profiling for the identification of fabry hemizygotes and heterozygotes. Clin. Chem. 2005, 51:688-694.
17. German J.B., Gillies L.A., Smilowitz J.T., Zivkovic A.M., Watkins S.M. Lipidomics and lipid profiling in metabolomics. Curr. Opin. Lipidol. 2007, 18:66-71.
18. Giovane A., Balestrieri A., Napoli C. New insights into cardiovascular and lipid metabolomics. J. Cell. Biochem. 2008, 105:648-654.
19. Gomez-Munoz A. Ceramide 1-phosphate/ceramide, a switch between life and death. Biochim. Biophys. Acta 2006, 1758:2049-2056.
20. Gonzalez-Covarrubias V., Beekman M., Uh H.W., Dane A., Troost J., Paliukhovich I., van der Kloet F.M., Houwing-Duistermaat J., Vreeken R.J., Hankemeier T., Slagboom E.P. Lipidomics of familial longevity. Aging Cell 2013, 12:426-434.
21. Goodacre R., Vaidyanathan S., Dunn W.B., Harrigan G.G., Kell D.B. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 2004, 22:245-252.
22. Gross R.W., Jenkins C.M., Yang J., Mancuso D.J., Han X. Functional lipidomics: the roles of specialized lipids and lipid-protein interactions in modulating neuronal function. Prostaglandins Other Lipid Mediat. 2005, 77:52-64.
23. Hait N.C., Allegood J., Maceyka M., Strub G.M., Harikumar K.B., Singh S.K., Luo C., Marmorstein R., Kordula T., Milstien S., Spiegel S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325:1254-1257.
24. Han X. Lipidomics: developments and applications. J. Chromatogr. B 2009, 877:2663.
25. Han X., Gross R.W. Global analysis of cellular lipidomes directly from crude extracts of biological samples by electrospray ionization mass spectrometry: a bridge to lipidomics. J. Lipid Res. 2003, 44:1071-1079.
26. Han X., Gross R.W. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 2005, 24:367-412.
27. Han X., Holtzman D., McKeel D.W., Kelley J., Morris J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 2002, 82:809-818.
28. Han X., Yang J., Cheng H., Yang K., Abendschein D.R., Gross R.W. Shotgun lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered substrate utilization with mitochondrial dysfunction. Biochemistry 2005, 44:16684-16694.
29. Han X., Yang J., Yang K., Zhao Z., Abendschein D.R., Gross R.W. Alterations in myocardial cardiolipin content and composition occur at the very earliest stages of diabetes: a shotgun lipidomics study. Biochemistry 2007, 46:6417-6428.
30. Harkewicz R., Dennis E.A. Applications of mass spectrometry to lipids and membranes. Annu. Rev. Biochem. 2011, 80:301-325.
31. Havel R.J., Hamilton R.L. Hepatic catabolism of remnant lipoproteins: where the action is. Arterioscler. Thromb. Vasc. Biol. 2004, 24:213-215.
32. Henry J.B. Diagnósticos clínicos e tratamentos por métodos laboratoriais 1999, Manole, São Paulo. 2nd ed.
33. Horn P.J., Chapman K.D. Lipidomics in tissues, cells and subcellular compartments. Plant J. 2012, 70:69-80.
34. Hu C., van der Heijden R., Wang M., van der Greef J., Hankemeier T., Xu G. Analytical strategies in lipidomics and applications in disease biomarker discovery. J. Chromatogr. B 2009, 877:2836-2846.
35. Hussain M.M. A proposed model for the assembly of chylomicrons. Atherosclerosis 2000, 148:1-15.
36. Ishii I., Fukushima N., Ye X., Chun J. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem. 2004, 73:321-354.
37. Ivanova P.T., Milne S.B., Forrester J.S., Brown H.A. Lipid arrays: new tools in the understanding of membrane dynamics and lipid signaling. Mol. Interv. 2004, 4:86-96.
38. Ivanova P.T., Milne S.B., Myers D.S., Brown H.A. Lipidomics: a mass spectrometry based systems level analysis of cellular lipids. Curr. Opin. Chem. Biol. 2009, 13:526-531.
39. Jia L., Wang C., Zhao S., Lu X., Xu G. Metabolomic identification of potential phospholipid biomarkers for chronic glomerulonephritis by using high performance liquid chromatography-mass spectrometry. J. Chromatogr. B 2007, 860:134-140.
40. Jové M., Ayala V., Ramírez-Núñez O., Serrano J.C., Cassanyé A., Arola L., Caimari A., Del Bas J.M., Crescenti A., Pamplona R., Portero-Otín M. Lipidomic and metabolomic analyses reveal potential plasma biomarkers of early atheromatous plaque formation in hamsters. Cardiovasc. Res. 2013, 97:642-652.
41. Kaddurah-Daouk R., Krishnan R.R.K. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacol. Rev. 2009, 34:173-186.
42. Kaddurah-Daouk R., McEvoy J., Baillie R.A., Lee D., Yao J.K., Doraiswamy P.M., Krishnan K.R. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 2007, 12:934-945.
43. Kaddurah-Daouk R., Baillie R.A., Zhu H., Zeng Z.B., Wiest M.M., Nguyen U.T., Watkins S.M., Krauss R.M. Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics study. Metabolomics 2010, 6:191-201.
44. Katajamaa M., Oresic M. Processing methods for differential analysis of LC/MS profile data. BMC Bioinforma. 2005, 6:179-190.
45. Kishimoto K., Urade R., Ogawa T., Moriyama T. Nondestructive quantification of neutral lipids by thin-layer chromatography and laser-fluorescent scanning: suitable methods for "lipidome" analysis. Biochem. Biophys. Res. Commun. 2001, 281:657-662.
46. Kolak M., Westerbacka J., Velagapudi V.R., Wågsäter D., Yetukuri L., Makkonen J., Rissanen A., Häkkinen A.M., Lindell M., Bergholm R., Hamsten A., Eriksson P., Fisher R.M., Oresic M., Yki-Järvinen H. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007, 56:1960-1968.
47. Kolak M., Gertow J., Westerbacka J., Summers S.A., Liska J., Franco-Cereceda A., Orešič M., Yki-Järvinen H., Eriksson P., Fisher R.M. Expression of ceramide-metabolising enzymes in subcutaneous and intra-abdominal human adipose tissue. Lipids Health Dis. 2012, 11:115. 10.1186/1476-511X-11-115.
48. Kulik W., van Lenthe H., Stet F.S., Houtkooper R.H., Kemp H., Stone J.E., Steward C.G., Wanders R.J., Vaz F.M. Bloodspot assay using HPLC-tandem mass spectrometry for detection of Barth syndrome. Clin. Chem. 2008, 54:371-378.
49. Ledeen R.W., Wu G. Sphingolipids of the nucleus and their role in nuclear signaling. Biochim. Biophys. Acta 2006, 1761:588-598.
50. Lee C.H., Olson P., Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207.
51. Li Q., Zhang Q., Wang C., Tang C., Zhang Y., Li N., Li J. Fish oil enhances recovery of intestinal microbiota and epithelial integrity in chronic rejection of intestinal transplant. PLoS ONE 2011, 6:e20460.
52. Li M., Yang L., Bai Y., Liu H. Analytical methods in lipidomics and their applications. Anal. Chem. 2014, 86:161-175.
53. Lieberman J.A., Koreen A.R. Neurochemistry and neuroendocrinology of schizophrenia, a selective review. Schizophr. Bull. 1993, 19:371-429.
54. Loizides-Mangold U. On the future of mass-spectrometry-based lipidomics. FEBS J. 2013, 280:2817-2829.
55. Mashaghi S., Jadidi T., Koenderink G., Mashaghi A. Lipid nanotechnology, Int. J. Mol. Sci. 2013, 14(2):4242-4282.
56. McEvoy J., Baillie R.A., Zhu H., Buckley P., Keshavan M.S., Nasrallah H.A., Dougherty G.G., Yao J.K., Kaddurah-Daouk R. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS ONE 2013, 8:e68717. 10.1371/journal.pone.0068717.
57. Meikle P., Barlow C., Weir J. Lipidomics and lipid biomarker discovery. Aust. Biochem. 2009, 40:12-16.
58. Meikle P.J., Wong G., Barlow C.K., Kingwell B.A. Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacol. Ther. 2014, 143:12-23.
59. Milne S., Ivanova P., Forrester J., Brown H.A. Lipidomics: an analysis of cellular lipids by ESI-MS. Methods 2006, 39:92-103.
60. Moore J.L., Caprioli R.M., Skaar E.P. Advanced mass spectrometry technologies for the study of microbial pathogenesis. Curr. Opin. Microbiol. 2014, 19:45-51.
61. Mouritsen O.G. Life-as a matter of fat. The Emerging Science of Lipidomics 2005, XIV. Springer, Heidelberg, (276 pp.).
62. Mouritsen O.G. Lipids, curvature, and nano-medicine. Eur. J. Lipid Sci. Technol. 2011, 113:1174-1187.
63. Murph M., Tanaka T., Pang J., Felix E., Liu S., Trost R., Godwin A.K., Newman R., Mills G. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol. 2007, 433:1-25.
64. Natarajan K., Mori N., Artemov D., Aboagye E.O., Chacko V.P., Bhujwalla Z.M. Phospholipid profiles of invasive human breast cancer cells are altered towards a less invasive phospholipid profile by the anti-inflammatory agent indomethacin. Adv. Enzym. Regul. 2000, 40:271-284.
65. Navas-Iglesias N., Carrasco-Pancorbo A., Cuadros-Rodríguez L. From lipids analysis towards lipidomics, a new challenge for the analytical chemistry of the 21st century. Part II: analytical lipidomics. Trends Anal. Chem. 2009, 28:393-403.
66. Niemoller T.D., Bazan N.G. Docosahexaenoic acid neurolipidomics. Prostaglandins Other Lipid Mediat. 2010, 91:85-89.
67. Ogretmen B., Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 2004, 4:604-616.
68. Oresic M. Metabolomics, a novel tool for studies of nutrition, metabolism and lipid dysfunction. Nutr. Metab. Cardiovasc. Dis. 2009, 19:816-824.
69. Oresic M., Hanninen V.A., Vidal-Puig A. Lipidomics: a new window to biomedical frontiers. Trends Biotechnol. 2008, 26:647-652.
70. Patti G.J., Yanes O., Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell Biol. 2012, 13:263-269.
71. Pelizzi N., Catinella S., Barboso S., Zanol M. Different electrospray tandem mass spectrometric approaches for rapid characterization of phospholipid classes of Curosurf, a natural pulmonary surfactant. Rapid Commun. Mass Spectrom. 2002, 16:2215-2220.
72. Petursdottir A.L., Farr S.A., Morley J.E., Banks W.A., Skuladottir G.V. Lipid peroxidation in brain during aging in the senescence-accelerated mouse (sam). Neurobiol. Aging 2007, 28:1170-1178.
73. Piomelli D., Astarita G., Rapaka R. A neuroscientist's guide to lipidomics. Nat. Rev. Neurosci. 2007, 8:743-754.
74. Postle A.D. Lipidomics. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15:127-133.
75. Rapaka R.S. Targeted lipidomics and drug abuse research. Prostaglandins Other Lipid Mediat. 2005, 77:219-222.
76. Rilfors L., Lindblom G. Regulation of lipids and lipid synthesizing enzymes. Colloids Surf. B: Biointerfaces 2002, 26:112-124.
77. Santana R.C.O. Influência da extração de lipídeos e da casca de diferentes fontes protéicas na digestibilidade in vitro Viçosa, MG: UFV, 71f. Mestrado em Bioquímica Agrícola 2008, (Dissertação), Universidade Federal de Viçosa, Viçosa.
78. Seppänen-Laakso T., Oresic M. How to study lipidomes. J. Mol. Endocrinol. 2009, 42:185-190.
79. Serhan C.N. Mediator lipidomics. Prostaglandins Other Lipid Mediat. 2005, 77:4-14.
80. Skosnik P.D., Yao J.K. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?. Prostaglandins Leukot. Essent. Fat. Acids 2003, 69:367-384.
81. Trifonova O., Lokhov P., Archakov A. Postgenomics diagnostics: metabolomics approaches to human blood profiling. OMICS 2013, 17:550-559.
82. Trimpin S., Tan B., Bohrer B.C., O'Dell D.K., Merenbloom S.I., Pazos M.X., Clemmer D.E., Walker J.M. Profiling of phospholipids and related lipid structures using multidimensional ion mobility spectrometry-mass spectrometry. Int. J. Mass Spectrom. 2009, 287:58-69.
83. Tsang T.M., Huang J.T., Holmes E., Bahn S. Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J. Proteome Res. 2006, 5:756-760.
84. Tsimikas S., Brilakis E.S., Miller E.R., McConnell J.P., Lennon R.J., Kornman K.S., Witztum J.L., Berger P.B. Oxidized phospholipids, lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 2005, 353:46-57.
85. van der Greef J., Stroobant P., van der Heijden R. The role of analytical sciences in medical systems biology. Curr. Opin. Chem. Biol. 2004, 8:559-565.
86. van Meer G. Cellular lipidomics. EMBO J. 2005, 24:3159-3165.
87. Viant M.R., Sommer U. Mass spectrometry based environmental metabolomics: a primer and review. Metabolomics 2013, 9:S144-S158.
88. Villas-Boas S.G., Gombert A.K. Análise do Metaboloma - Uma ferramenta biotecnológica emergente na era pós - genÔmica. Biotecnol. Cienc. Desenvolv. 2006, 36:58-69.
89. Wang Y., Rimm E.B., Stampfer M.J., Willett W.C., Hu F.B. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am. J. Clin. Nutr. 2005, 81:555-563.
90. Wenk M.R. The emerging field of lipidomics. Nat. Rev. Drug Discov. 2005, 4:594-610.
91. Wenk M.R. Lipidomics: new tools and applications. Cell 2010, 143:888-895.
92. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 2005, 10:538-544.
93. Wu J., Chan R., Wenk M.R., Hew C.L. Lipidomic study of intracellular Singapore grouper iridovirus. Virology 2010, 399:248-256.
94. Xiao Y.J., Schwartz B., Washington M., Kennedy A., Webster K., Belinson J., Xu Y. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal. Biochem. 2001, 290:302-313.
95. Yetukuri L., Katajamaa M., Medina-Gomez G., Seppänen-Laakso T., Vidal-Puig A., Oresic M. Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst. Biol. 2007, 1:12.
96. Yetukuri L., Ekroos K., Vidal-Puig A., Oresic M. Informatics and computational strategies for the study of lipids. Mol. BioSyst. 2008, 4:121-127.